Eledon Pharmaceuticals, Inc. (ELDN): Price and Financial Metrics
GET POWR RATINGS... FREE!
ELDN Stock Price Chart Interactive Chart >
ELDN Price/Volume Stats
Current price | $3.29 | 52-week high | $4.39 |
Prev. close | $3.32 | 52-week low | $2.03 |
Day low | $3.24 | Volume | 5,354 |
Day high | $3.37 | Avg. volume | 18,794 |
50-day MA | $2.68 | Dividend yield | N/A |
200-day MA | $2.90 | Market Cap | 45.26M |
Eledon Pharmaceuticals, Inc. (ELDN) Company Bio
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease.
Latest ELDN News From Around the Web
Below are the latest news stories about ELEDON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ELDN as an investment opportunity.
Eledon Pharmaceuticals Provides Business and Pipeline UpdatesCompany plans to prioritize and focus resources on the advancement of tegoprubart in kidney transplantation Continued enrollment in open-label Phase 1b kidney transplant trial with initial data release expected at the World Congress of Nephrology in March 2023 Phase 2 BESTOW trial planned to evaluate tegoprubart for the prevention of rejection in patients receiving a kidney transplant with site initiation anticipated in mid-2023 Deprioritize clinical development of tegoprubart in IgA Nephropathy |
eGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies-Agreement leverages Eledon’s investigational anti-CD40L antibody, tegoprubart, as part of eGenesis’ immunosuppression regimen that prevents xenotransplant rejection in nonhuman primate recipients- -Establishes framework for use of tegoprubart for preclinical xenotransplantation studies in support of eGenesis’ kidney, heart and islet cell programs- CAMBRIDGE, Mass. and IRVINE, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- eGenesis, Inc. (“eGenesis”) and Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDA |
C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring SystemEledon to Incorporate the iBox Scoring System in Future Kidney Transplant TrialsIRVINE, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path) announced on December 20, 2022, that its Transplant Therapeutic Consortium (TTC) received a qualification opinion for the iBox Scoring System as a novel secondary efficacy endpoint for kidney transplant clinical trials through the European Medicines Agency's (EMA) qualification of novel methodologies for drug development. This novel se |
Eledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial ResultsReceived FDA clearance of IND application to evaluate tegoprubart in a Phase 2 trial for the prevention of rejection in patients receiving a kidney transplant Dosed initial two patients in ex-U.S. Phase 1b trial evaluating tegoprubart for the prevention of rejection in patients receiving a kidney transplant Received FDA clearance of IND application to evaluate tegoprubart for the treatment of IgA Nephropathy (IgAN) Conference call today at 4:30 PM ET IRVINE, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE |
Eledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022Management to host conference call and webcast at 4:30 pm ETIRVINE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that it plans to release financial results for the third quarter ended September 30, 2022 on Monday, November 14, after the close of trading. Eledon’s management team will host a conference call and webcast beginning at 4:30 p.m. ET. Conference Call and Webcast Details:Monday, November 14, 2022 at 4:30 p.m. Eastern T |
ELDN Price Returns
1-mo | 51.61% |
3-mo | 42.42% |
6-mo | 9.30% |
1-year | -7.58% |
3-year | -67.36% |
5-year | N/A |
YTD | 44.30% |
2022 | -48.30% |
2021 | -71.36% |
2020 | N/A |
2019 | N/A |
2018 | N/A |
Loading social stream, please wait...